Combination Use of Tegafur and Apatinib As First-Line Therapy in Treatment of Advanced Gastric Cancer: A Single-Blinded Randomized Study

Overview

Journal Gastroenterol Res Pract

Publisher Wiley

Specialty Gastroenterology

Date 2020 Apr 25

PMID 32328095

Citations 2

Authors

Chaofeng Li

Tao Tang

Wenyue Wang

Affiliations

Soon will be listed here.

Abstract

Objective: To investigate the efficacy and safety of the combination use of tegafur and apatinib as a first-line therapy strategy in advanced gastric cancer (GC).

Methods: The present study included a total of 62 advanced GC patients. The patients were randomized into the combined group (treated with both tegafur and apatinib) and the control group (treated with only tegafur). Treatment efficacy, KPS score, nutrition condition, and progression-free survival time (PFS) were recorded.

Results: Both the response and disease control rates were significantly higher in the combined group. The PFS time was remarkably higher and the KPS score was significantly reduced in the combined group after treatment. After treatment, both groups showed significantly increased nutrition risk, but the rates of patients with nutrition risk or innutrition were remarkably higher in the combined group. The ADR rates were also significantly higher in the combined group.

Conclusion: The combination use could achieve good efficacy and prolong patients' PFS time; however, apatinib also reduced the patients' quality of life and enhanced the nutrition risk and adverse drug reactions.

Citing Articles

Perioperative use of enteral nutrition with ω-3 polyunsaturated fatty acid in patients with gastric cancer: a meta-analysis.

Fu T, Hu W, Chang L, Duan J Front Oncol. 2024; 14:1488229.

PMID: 39469648 PMC: 11513252. DOI: 10.3389/fonc.2024.1488229.

Clinical progress of anti-angiogenic targeted therapy and combination therapy for gastric cancer.

Xu D, Luo Y, Wang P, Li J, Ma L, Huang J Front Oncol. 2023; 13:1148131.

PMID: 37384288 PMC: 10295723. DOI: 10.3389/fonc.2023.1148131.

References

Jeen Y, Yoon S, Shin S, Kim B, Mok Y, Kim C . Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma. Cancer. 2001; 91(12):2288-93. View

Peng H, Zhang Q, Li J, Zhang N, Hua Y, Xu L . Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget. 2016; 7(13):17220-9. PMC: 4941382. DOI: 10.18632/oncotarget.7948. View

Thiel A, Ristimaki A . Targeted therapy in gastric cancer. APMIS. 2015; 123(5):365-72. DOI: 10.1111/apm.12359. View

Casadei Gardini A, Scarpi E, Faloppi L, Scartozzi M, Silvestris N, Santini D . Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib. Oncotarget. 2016; 7(41):67142-67149. PMC: 5341863. DOI: 10.18632/oncotarget.11565. View

Matt P, van Zwieten-Boot B, Calvo Rojas G, Ter Hofstede H, Garcia-Carbonero R, Camarero J . The European Medicines Agency review of Tegafur/Gimeracil/Oteracil (Teysuno™) for the treatment of advanced gastric cancer when given in combination with cisplatin: summary of the Scientific Assessment of the Committee for medicinal products for.... Oncologist. 2011; 16(10):1451-7. PMC: 3228070. DOI: 10.1634/theoncologist.2011-0224. View

Oba K, Paoletti X, Bang Y, Bleiberg H, Burzykowski T, Fuse N . Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer. 2013; 49(7):1565-77. DOI: 10.1016/j.ejca.2012.12.016. View

Brower V . Modified gastric cancer chemotherapy: more effective, less toxic. Lancet Oncol. 2015; 16(16):e590. DOI: 10.1016/S1470-2045(15)00442-8. View

Shen L, Shan Y, Hu H, Price T, Sirohi B, Yeh K . Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncol. 2013; 14(12):e535-47. DOI: 10.1016/S1470-2045(13)70436-4. View

Chen A, Setser A, Anadkat M, Cotliar J, Olsen E, Garden B . Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012; 67(5):1025-39. DOI: 10.1016/j.jaad.2012.02.010. View

10.

de Martel C, Forman D, Plummer M . Gastric cancer: epidemiology and risk factors. Gastroenterol Clin North Am. 2013; 42(2):219-40. DOI: 10.1016/j.gtc.2013.01.003. View

11.

Basile D, Garattini S, Bonotto M, Ongaro E, Casagrande M, Cattaneo M . Immunotherapy for colorectal cancer: where are we heading?. Expert Opin Biol Ther. 2017; 17(6):709-721. DOI: 10.1080/14712598.2017.1315405. View

12.

Hartgrink H, Jansen E, van Grieken N, van de Velde C . Gastric cancer. Lancet. 2009; 374(9688):477-90. PMC: 4613761. DOI: 10.1016/S0140-6736(09)60617-6. View

13.

Fuchs C, Tomasek J, Yong C, Dumitru F, Passalacqua R, Goswami C . Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2013; 383(9911):31-39. DOI: 10.1016/S0140-6736(13)61719-5. View

14.

Yu J, Zhang Y, Leung L, Liu L, Yang F, Yao X . Efficacy and safety of angiogenesis inhibitors in advanced gastric cancer: a systematic review and meta-analysis. J Hematol Oncol. 2016; 9(1):111. PMC: 5070169. DOI: 10.1186/s13045-016-0340-8. View

15.

Geng R, Li J . Apatinib for the treatment of gastric cancer. Expert Opin Pharmacother. 2014; 16(1):117-22. DOI: 10.1517/14656566.2015.981526. View

16.

Tong X, Wang F, Liang S, Zhang X, He J, Chen X . Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells. Biochem Pharmacol. 2012; 83(5):586-97. DOI: 10.1016/j.bcp.2011.12.007. View

17.

Li W, Zhao X, Wang H, Liu X, Zhao X, Huang M . Maintenance treatment of Uracil and Tegafur (UFT) in responders following first-line fluorouracil-based chemotherapy in metastatic gastric cancer: a randomized phase II study. Oncotarget. 2016; 8(23):37826-37834. PMC: 5514953. DOI: 10.18632/oncotarget.13922. View

18.

Chen W, Yu J, Zhang Y, Wang W, Yu W, Shi X . First-line application of apatinib combined with S-1 based on peripheral circulating tumor cell screening to treat advanced gastric adenocarcinoma: a case report. Ann Transl Med. 2019; 7(8):181. PMC: 6526264. DOI: 10.21037/atm.2019.03.68. View

19.

Roviello G, Ravelli A, Polom K, Petrioli R, Marano L, Marrelli D . Apatinib: A novel receptor tyrosine kinase inhibitor for the treatment of gastric cancer. Cancer Lett. 2016; 372(2):187-91. DOI: 10.1016/j.canlet.2016.01.014. View

20.

Ferro A, Peleteiro B, Malvezzi M, Bosetti C, Bertuccio P, Levi F . Worldwide trends in gastric cancer mortality (1980-2011), with predictions to 2015, and incidence by subtype. Eur J Cancer. 2014; 50(7):1330-44. DOI: 10.1016/j.ejca.2014.01.029. View